We Offer Worldwide Shipping
Login Wishlist

Jolkinonlide A

$930

  • Brand : BIOFRON

  • Catalogue Number : AV-B04241

  • Specification : 98%

  • CAS number : 37905-07-0

  • Formula : C20H26O3

  • Molecular Weight : 314.42

  • PUBCHEM ID : 161953

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B04241

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

314.42

Appearance

Cryst.

Botanical Source

Structure Type

Diterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC1=C2C3C4(O3)CCC5C(CCCC5(C4C=C2OC1=O)C)(C)C

Synonyms

2H-Oxireno[1,10a]phenanthro[3,2-b]furan-10(11bH)-one, 3,3a,4,5,6,7,7a,7b-octahydro-4,4,7a,11-tetramethyl-, (1aS,3aR,7aR,7bS,11bR)-/(5β,9β,10α,14β)-8,14:12,16-Diepoxyabieta-11,13(15)-dien-16-one/Jolkinolide A

IUPAC Name

(1S,3R,10S,11R,16R)-5,11,15,15-tetramethyl-2,7-dioxapentacyclo[8.8.0.01,3.04,8.011,16]octadeca-4,8-dien-6-one

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

206.7±23.3 °C

Boiling Point

479.5±45.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C20H26O3/c1-11-15-12(22-17(11)21)10-14-19(4)8-5-7-18(2,3)13(19)6-9-20(14)16(15)23-20/h10,13-14,16H,5-9H2,1-4H3/t13-,14+,16-,19-,20+/m1/s1

InChl Key

OYXDHOVYZKWSRM-PHJMNMFVSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:37905-07-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28338342

Abstract

A novel and simple method was established for the extraction and determination of jolkinolide A and B in Euphorbia fischeriana Steud. using matrix solid-phase dispersion (MSPD) extraction and high-performance liquid chromatography (HPLC). The optimised conditions for the MSPD extraction were determined to be that silica gel was served as dispersant, the mass ratio of sample to silica gel was selected to be 1:4, and 5 mL of acetonitrile was used as elution solvent. The method exhibited a good performance in terms of linearity (r2 ≥ 0.9997) and the limits of detection in the range of 0.052-0.065 μg mL-1. The recoveries were in the range of 90.2-98.9% with relative standard deviations (RSDs) ranging from 1.3 to 3.5%. The extraction efficiencies obtained by the MSPD were higher than other extraction method with less cost of sample and solvent. At last, the optimised method was applied for analysing real samples.

KEYWORDS

Euphorbia fischeriana Steud; Matrix solid-phase dispersion; jolkinolide A; jolkinolide B; liquid chromatography

Title

Development of matrix solid-phase dispersion coupled with high-performance liquid chromatography for determination of jolkinolide A and jolkinolide B in Euphorbia fischeriana Steud.

Author

Cai D1, Zhai W2, Zhang Q1, Liu J1, Sun Y1, Liu L1, Liu J1.

Publish date

2017 Aug;

PMID

28087861

Abstract

BACKGROUND Jolkinolide A (JA) and Jolkinolide B (JB) are diterpenoids extracted from the roots of Euphorbia fischeriana Steud and have been shown to have anti-tumor activity. However, their effects on the ability of tumor cells to invade blood vessels and metastasize remain largely unknown. Investigations into the effects of JA and JB on the angiogenesis of tumor tissues may facilitate the identification of new natural drugs with anti-tumor growth and metastasis activities. MATERIAL AND METHODS We used different concentrations of JA and JB (20 μg/ml, 40 μg/ml, 60 μg/ml, 80 μg/ml, and 100 μg/ml) to stimulate A549 cells and then studied the effects on the growth and metastasis of lung cancers. In addition, we used conditional media from A549 cells (A549-CM) stimulated by either JA or JB in different concentrations to culture human umbilical vein endothelial cells (HUVECs). RESULTS We found that both JA and JB significantly inhibited the Akt-STAT3-mTOR signaling pathway and reduced the expression of VEGF in A549 cells, but JB exhibited more significant inhibitory effects than JA. The JB-stimulated A549 cell conditional media had a greater inhibitory effect on the proliferation and migration of HUVECs than did the conditional media of JA-stimulated A549 cells. This effect gradually increased with increasing concentrations of either type of Jolkinolide. CONCLUSIONS Our results suggest that JA and JB inhibited VEGF expression in A549 cells through the inhibition of the Akt-STAT3-mTOR signaling pathway, and directly inhibited the proliferation and migration of HUVECs. These findings are of great significance for the development of new plant-derived chemotherapy agents for the treatment of cancer.

Title

Jolkinolide A and Jolkinolide B Inhibit Proliferation of A549 Cells and Activity of Human Umbilical Vein Endothelial Cells.

Author

Shen L1,2, Zhang SQ2, Liu L1, Sun Y1, Wu YX2, Xie LP2, Liu JC1.

Publish date

2017 Jan 14

PMID

26456501

Abstract

Osteoclasts (OC) are bone-specific multinucleated giant cells (MNCs) derived from the monocyte/macrophage hematopoietic lineage cells. Inhibiting osteoclast formation is considered as an effective therapeutic approach for the treatment of the pathological bone loss. In this study, we investigated effects of 17-hydroxy-jolkinolide A (HJA), an ent-abietane diterpenoid isolated from the dried root of Euphorbia fischeriana, on osteoclastogenesis induced by RANKL. The results showed that HJA significantly inhibited RANKL-induced osteoclast formation from primary bone marrow macrophages (BMMs). HJA also prevented bone resorption by mature osteoclasts in a dose-dependent manner. In addition, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (Cts K) and MMP-9, was significantly inhibited by HJA. Furthermore, HJA also significantly inhibited RANKL-induced activation of NF-κB and phosphorylation of MAPK. Our results indicate that HJA has an inhibitory role in the bone loss by preventing osteoclast formation as well as its bone resorptive activity. Therefore, HJA may be useful as a therapeutic reagent for bone loss-associated diseases.

Copyright ? 2015 Elsevier B.V. All rights reserved.

KEYWORDS

17-Hydroxy-jolkinolide A; Bone resorption; MAPK; NF-κB; Osteoclast; RANKL

Title

17-Hydroxy-jolkinolide A inhibits osteoclast differentiation through suppressing the activation of NF-κB and MAPKs.

Author

Wang Y1, Xu X2, Wang HB3, Wu D4, Li XO5, Peng Q2, Liu N6, Sun WC7.

Publish date

2015 Dec


Description :

837